EXACT Therapeutics Management
Management criteria checks 4/4
EXACT Therapeutics' CEO is Per Walday, appointed in Jun 2022, has a tenure of 2.92 years. total yearly compensation is NOK2.75M, comprised of 92.9% salary and 7.1% bonuses, including company stock and options. directly owns 0.017% of the company’s shares, worth NOK27.51K. The average tenure of the management team and the board of directors is 2.8 years and 3.4 years respectively.
Key information
Per Walday
Chief executive officer
NOK 2.8m
Total compensation
| CEO salary percentage | 92.92% |
| CEO tenure | 2.9yrs |
| CEO ownership | 0.02% |
| Management average tenure | 2.8yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation
Aug 09
Is EXACT Therapeutics (OB:EXTX) In A Good Position To Invest In Growth?
Apr 20We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth
Sep 07We're Hopeful That EXACT Therapeutics (OB:EXTX) Will Use Its Cash Wisely
May 06Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation
Dec 30Companies Like EXACT Therapeutics (OB:EXTX) Are In A Position To Invest In Growth
Sep 15EXACT Therapeutics (OB:EXTX) Is In A Good Position To Deliver On Growth Plans
Jan 31We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth
Aug 21We're Not Very Worried About EXACT Therapeutics' (OB:EXTX) Cash Burn Rate
May 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | NOK 3m | NOK 3m | -NOK 52m |
| Sep 30 2024 | n/a | n/a | -NOK 54m |
| Jun 30 2024 | n/a | n/a | -NOK 55m |
| Mar 31 2024 | n/a | n/a | -NOK 52m |
| Dec 31 2023 | NOK 3m | NOK 2m | -NOK 48m |
| Sep 30 2023 | n/a | n/a | -NOK 42m |
| Jun 30 2023 | n/a | n/a | -NOK 36m |
| Mar 31 2023 | n/a | n/a | -NOK 38m |
| Dec 31 2022 | NOK 2m | NOK 1m | -NOK 40m |
Compensation vs Market: Per's total compensation ($USD272.74K) is about average for companies of similar size in the Norwegian market ($USD345.01K).
Compensation vs Earnings: Per's compensation has been consistent with company performance over the past year.
CEO
Per Walday (64 yo)
Dr. Per Walday, Ph D., has been the Chief Executive Officer at PCI Biotech AS since 2008. He serves as Chief Executive Officer at EXACT Therapeutics AS since June 5, 2022.Dr. Walday had been the Chief Exe...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 2.9yrs | NOK 2.75m | 0.017% NOK 26.6k | |
| Co Founder & COO | no data | NOK 1.73m | 4.78% NOK 7.4m | |
| Chief Financial Officer | 2.6yrs | NOK 2.27m | 0.011% NOK 16.4k | |
| Director | 2.9yrs | NOK 450.00k | 4.27% NOK 6.6m | |
| Chief Medical Officer | 2.7yrs | NOK 2.72m | 0.011% NOK 16.4k | |
| Chief Business Officer | 1.5yrs | NOK 1.73m | 0.0066% NOK 10.3k | |
| Founder | no data | NOK 2.49m | 2.88% NOK 4.5m | |
| Vice President of Technology | 3.1yrs | no data | no data |
Experienced Management: EXTX's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Director | 10.3yrs | NOK 450.00k | 4.27% NOK 6.6m | |
| Director | 7.3yrs | NOK 157.50k | 0.55% NOK 852.8k | |
| Director | less than a year | NOK 170.00k | no data | |
| Chair of the Board | 3.4yrs | NOK 515.00k | 0.12% NOK 179.4k | |
| Vice Chairman | less than a year | no data | no data | |
| Director | 3.9yrs | NOK 300.00k | no data | |
| Director | less than a year | no data | no data |
Experienced Board: EXTX's board of directors are considered experienced (3.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 18:24 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
EXACT Therapeutics AS is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.